Samrat Pharmachem Ltd-$
Samrat Pharmachem Ltd-$ (SAMRATPH) is scheduled to report results on 14 Nov 2026. Samrat Pharmachem Ltd-$ last reported results for the quarter ended Jun 2026, with sales of ₹79.76 crore and net profit of ₹0.88 crore. The stock last traded at ₹244, a market capitalisation of ₹75.3 crore. Over the past 52 weeks the stock has ranged between ₹190 and ₹312. Figures are as of 6 Oct 2026 and are not real time.
Samrat Pharmachem Ltd-$ share price and key metrics
- Current price
- ₹244
- Market cap
- ₹75.3 cr
- Book value
- ₹221
- ROE
- -5.19%
- ROCE
- -2.88%
- Dividend yield
- 0.00%
- 52w high / low
- 312/190
Metrics as of 6 Oct 2026. Not real time.
Track Samrat Pharmachem Ltd-$
Cruxal reads every Samrat Pharmachem Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Samrat Pharmachem Ltd-$ growth and returns
- 10 Years
- 16%
- 5 Years
- 10%
- 3 Years
- -2%
- TTM
- 5%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -146%
- 10 Years
- 20%
- 5 Years
- 3%
- 3 Years
- -15%
- 1 Year
- -22%
- 10 Years
- 14%
- 5 Years
- 13%
- 3 Years
- 2%
- Last Year
- -5%
Samrat Pharmachem Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹79.76 cr, up 5.4% from ₹75.65 cr a year earlier. Net profit turned positive at ₹0.88 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 70.17 | 63.66 | 71.2 | 75.65 | 78.87 | 63.43 | 71.77 | 79.76 |
| Expenses | 66.8 | 59.48 | 71.07 | 75.52 | 79.23 | 64.08 | 73.01 | 78.87 |
| Operating profit | 3.37 | 4.18 | 0.13 | 0.13 | -0.36 | -0.65 | -1.24 | 0.89 |
| OPM % | 4.80% | 6.57% | 0.18% | 0.17% | -0.46% | -1.02% | -1.73% | 1.12% |
| Other income | 0.49 | 0 | -0.11 | 0.69 | 0.05 | 0.4 | -0.31 | 0.99 |
| Interest | 0.17 | 0.1 | 0.22 | 0.44 | 0.26 | 0.13 | 0.14 | 0.11 |
| Depreciation | 0.17 | 0.17 | 0.16 | 0.17 | 0.18 | 0.19 | 0.19 | 0.19 |
| Profit before tax | 3.52 | 3.91 | -0.36 | 0.21 | -0.75 | -0.57 | -1.88 | 1.58 |
| Tax % | 24.43% | 28.90% | 11.11% | 209.52% | -21.33% | -19.30% | 8.51% | 44.94% |
| Net profit | 2.66 | 2.78 | -0.4 | -0.23 | -0.59 | -0.46 | -2.04 | 0.88 |
| EPS (₹) | 8.61 | 9.00 | -1.29 | -0.74 | -1.91 | -1.49 | -6.60 | 2.85 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Samrat Pharmachem Ltd-$ annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 73 | 93 | 111 | 137 | 179 | 222 | 311 | 282 | 286 | 290 | 294 |
| Operating profit | 4 | 6 | 3 | 7 | 9 | 24 | 24 | 2 | 10 | -2 | -1 |
| OPM % | 5% | 6% | 2.9% | 4.8% | 4.8% | 11% | 8% | 0.9% | 3.6% | -0.7% | -0.5% |
| Net profit | 2 | 3 | 2 | 4 | 5 | 17 | 17 | 2 | 7 | -3 | -2 |
| EPS (₹) | 5.66 | 10.42 | 4.98 | 13.72 | 17.25 | 55.60 | 53.82 | 6.99 | 23.01 | -10.71 | -7.15 |
TTM is the trailing twelve months to the most recent quarter.
Samrat Pharmachem Ltd-$ balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 62 | 69 | 65 |
| Borrowings | 7 | 9 | 7 | 9 | 9 | 8 | 19 | 8 | 10 | 11 |
| Other liabilities | 14 | 13 | 14 | 25 | 19 | 30 | 35 | 48 | 40 | 46 |
| Total liabilities | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 122 | 124 |
| Fixed assets | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 | 10 | 12 |
| CWIP | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 4 |
| Other assets | 29 | 34 | 33 | 50 | 48 | 75 | 104 | 108 | 107 | 108 |
| Total assets | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 122 | 124 |
As reported by the company. Total assets equal total liabilities by construction.
Samrat Pharmachem Ltd-$ cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -3 | 0 | 2 | -1 | 5 | 17 | -9 | 9 | -10 | 9 |
| Cash from investing | 1 | -2 | 2 | -2 | -3 | -1 | -3 | -0 | 0 | -3 |
| Cash from financing | 1 | 2 | -4 | 2 | -2 | -2 | 10 | -11 | 0 | -0 |
| Net cash flow | -1 | -1 | 1 | -1 | -0 | 14 | -3 | -2 | -10 | 6 |
| Free cash flow | -4 | -0 | 2 | -3 | 3 | 16 | -11 | 9 | -11 | 6 |
| CFO / operating profit | -73% | 17% | 126% | -7% | 81% | 78% | 0% | 503% | -84% | -493% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Samrat Pharmachem Ltd-$ operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 16% | 23% | 12% | 22% | 24% | 52% | 35% | 3% | 13% | -3% |
| Debtor days | 59 | 86 | 69 | 74 | 67 | 72 | 61 | 90 | 72 | 64 |
| Inventory days | 41 | 31 | 28 | 55 | 25 | 24 | 43 | 28 | 52 | 56 |
| Days payable | 43 | 46 | 45 | 67 | 39 | 45 | 42 | 65 | 53 | 55 |
| Cash conversion cycle | 58 | 70 | 52 | 61 | 53 | 51 | 62 | 53 | 71 | 65 |
| Working capital days | 34 | 32 | 37 | 39 | 36 | 32 | 40 | 47 | 68 | 52 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Samrat Pharmachem Ltd-$ shareholding pattern
Promoters held 49.09% at Jun 2026, broadly unchanged since Jun 2025. FIIs 3.24% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 48.95% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% |
| FIIs | 3.24% | 3.24% | 3.24% | 0.00% | 3.24% | 3.24% | 3.24% | 3.24% |
| DIIs | 0.00% | 0.00% | 0.00% | 3.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 47.81% | 47.66% | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% | 47.66% |
| No. of shareholders | 6,984 | 6,844 | 6,785 | 6,752 | 6,699 | 6,488 | 6,311 | 6,330 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Samrat Pharmachem Ltd-$’s next results date?
Samrat Pharmachem Ltd-$’s next results are scheduled for 14 Nov 2026.
- Earnings resultsConsider and take on record the Un-Audited Financial Results for the quarter ended September 30, 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Samrat Pharmachem Ltd-$ corporate filings
- Samrat Pharmachem Limited schedules Board Meeting for November 14, 2026, to consider Q2 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Samrat Pharmachem Limited has issued a formal notice for a Board of Directors meeting to…
Read the full analysis - Trading window shall remain closed from 01-10-2026 till 48 hours after declaration of UFR for the quarter ended September 30, 2026.Insider Trading / SASTlow impact
- Samrat Pharmachem Limited Announces Statutory Auditor Change Following Tenure ExpiryCompany Updatelow impact
Cruxal's analysis: Samrat Pharmachem Limited has formally announced the appointment of M/s Divyesh J Shah &…
Read the full analysis - Samrat Pharmachem Limited concludes 34th Annual General Meeting with all resolutions passedAGM/EGMlow impact
Cruxal's analysis: Samrat Pharmachem Limited has successfully concluded its 34th Annual General Meeting held…
Read the full analysis - Samrat Pharmachem Limited reports FY26 financial performance with revenue of 289.72 crore and negative EBITDA of 3.94 croreAGM/EGMhigh impact
Cruxal's analysis: Samrat Pharmachem Limited held its 34th Annual General Meeting, disclosing FY26 revenue…
Read the full analysis - Samrat Pharmachem Limited Announces 34th Annual General Meeting and Book Closure DatesCompany Updatelow impact
Cruxal's analysis: Samrat Pharmachem Limited has scheduled its 34th Annual General Meeting (AGM) for…
Read the full analysis - Samrat Pharmachem Ltd announces book closure dates for September 2026Corp. Actionlow impact
Cruxal's analysis: Samrat Pharmachem Ltd has notified that its Register of Members and Share Transfer books…
Read the full analysis - Samrat Pharmachem Limited schedules 34th Annual General Meeting for September 23, 2026AGM/EGMlow impact
Cruxal's analysis: Samrat Pharmachem Limited has announced that its 34th Annual General Meeting (AGM) will…
Read the full analysis - Samrat Pharmachem Ltd releases 34th Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Samrat Pharmachem Ltd has filed its 34th Annual Report for the financial year 2025-26…
Read the full analysis - Samrat Pharmachem Limited Reports Q1 FY2027 Financial Results with Turnaround to ProfitabilityCompany Updatemedium impact
Cruxal's analysis: Samrat Pharmachem Limited has declared its standalone unaudited financial results for the…
Read the full analysis - Samrat Pharmachem Limited Reports Turnaround with Q1 FY27 Profit of 87.60 LakhsBoard Meetinghigh impact
Cruxal's analysis: Samrat Pharmachem Limited has reported a significant financial turnaround for the quarter…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.